Hem › Myelodysplastiska syndrom › Massachusetts › Boston
Kliniska studier för Myelodysplastiska syndrom i Boston, MA
19 studier för Myelodysplastiska syndrom söker deltagare vid platser i och runt Boston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RekryterarFas 2
- Tufts Medical Center, Boston
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RekryterarFas 1
- Dana-Farber Cancer Institute, Boston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekryterarFas 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
RekryterarFas 1/2
- Dana-Farber Cancer Institute, Boston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RekryterarFas 3
- Massachusetts General Hospital, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekryterarFas 1/2
- Dana-Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
RekryterarFas 1Friska volontärer välkomna
- Brigham and Women's Hospital, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
RekryterarFas 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
RekryterarFas 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RekryterarObservationsstudie
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekryterarFas 2/3
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
RekryterarFas 1
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RekryterarFas 2Friska volontärer välkomna
- DFCI/BWH Brigham and Women's Hospital, Boston
IS-free Treg HaploHCT
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
Rekryterar
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
RekryterarFas 1
- Massachusetts General Hospital, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RekryterarFas 1
- Dana-Farber Cancer Institute, Boston
Myelodysplastiska syndrom-studier i andra städer
- Houston, TX43 studier
- Baldwin Park, CA26 studier
- New York City, NY21 studier
- Seattle, WA21 studier
- Washington, DC20 studier
- Tampa, FL19 studier
- Miami, FL17 studier
- Columbus, OH14 studier
- Durham, NC14 studier
- Chicago, IL13 studier
- Atlanta, GA13 studier
- St. Louis, MO13 studier
Andra studier i Boston
- Bröstcancer111 studier
- Icke-småcellig lungcancer90 studier
- Cancer (alla typer)86 studier
- Kolorektal cancer63 studier
- Metastaserande cancer63 studier
- Lungcancer62 studier
- Äggstockscancer61 studier
- Prostatacancer59 studier
- Depression52 studier
- Endometriecancer50 studier
- Hjärtsvikt44 studier
- Akut myeloid leukemi44 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.